Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Canadian Cancer Trials Group
Exscientia AI Limited
Zumutor Biologics Inc.
Arcus Biosciences, Inc.
Sotio Biotech Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
Rondo Therapeutics
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
BeOne Medicines
Tizona Therapeutics, Inc
City of Hope Medical Center
Innate Pharma
Dren Bio
Novartis
OncoNano Medicine, Inc.
NeoTX Therapeutics Ltd.
Bolt Biotherapeutics, Inc.
Nuvation Bio Inc.
National Cancer Institute (NCI)
Nanobiotix
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Nurix Therapeutics, Inc.
Exelixis
Xencor, Inc.
Numab Therapeutics AG
Incyte Corporation
Genentech, Inc.
NextPoint Therapeutics, Inc.
M.D. Anderson Cancer Center
Monopar Therapeutics
Monopar Therapeutics
Theratechnologies
Seagen Inc.
Novartis
Vincerx Pharma, Inc.
AstraZeneca
Xencor, Inc.
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
Eli Lilly and Company
Ikena Oncology
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
QuantumLeap Healthcare Collaborative